Arrowhead Research Corporation (ARWR)

Arrowhead Pharmaceuticals (ARWR) stock hits a 52-week high, fueled by FDA Breakthrough Therapy Designation and a Novartis collaboration. Increased social media buzz and a raised price target from Piper Sandler amplify positive momentum.

About Arrowhead Research Corporation

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene-silencing medicines for intractable diseases.
Arrowhead Research Corporation uses the ticker $ARWR for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Arrowhead Research Corporation (ARWR) sentiment is up 49.25% from the previous week.

Price: $63.80

Price 24-Hour Time-Series Raw Data
The stock price is strongly positive, reaching a 52-week high, supported by recent positive news like FDA Breakthrough Therapy Designation and a Novartis collaboration. Increased social media mentions and trading volume, along with a raised price target from Piper Sandler, are amplifying this upward momentum.

24-Hour: 4.4% 7-Day: -1.12% 30-Day: -0.03%

1-Year High: $73 on 2026-02-02
1-Year Low: $10 on 2025-04-08

AltRank: [---]

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Arrowhead Research Corporation (ARWR) is currently AltRank #502 based on combined combined social and market metrics Daily Average: [---]
[--] Week: [---] +10
[--] Month: [---] +61
[--] Months: [---] +420
[--] Year: [---] +65
1-Year High: [-----] on 2025-06-01
1-Year Low: [--] on 2025-03-15

Galaxy Score: [-----]

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +2
[--] Month: [--] +13
[--] Months: [--] [---]
[--] Year: [--] +6
1-Year High: [--] on 2025-09-02
1-Year Low: [--] on 2025-09-16

Engagements: [-----] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [------] -73%
[--] Month: [-------] -64%
[--] Months: [---------] +95%
[--] Year: [---------] +64%
1-Year High: [-------] on 2026-01-06
1-Year Low: [-----] on 2025-05-17

Engagements by network (24h): Reddit: [--] X: [-----] YouTube: [--] TikTok: [--]

Mentions: [---] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [---] -25%
[--] Month: [-----] -28%
[--] Months: [-----] +87%
[--] Year: [-----] +79%
1-Year High: [---] on 2025-11-28
1-Year Low: [--] on 2025-06-14

Mentions by network (24h): Reddit: [--] X: [---] YouTube: [--] TikTok: [--]

Creators: [---] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning Arrowhead Research Corporation (ARWR) in the last [--] hours which is up 62% from [--] in the previous [--] hours Daily Average: [--]
[--] Week: [---] -32%
[--] Month: [---] -22%
[--] Months: [-----] +24%
[--] Year: [-----] +62%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-28

The most influential creators that mention Arrowhead Research Corporation in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@CharlieQuiTrade	[--]	[--]	[--]	[---]
@WallStPirate	[--]	[---]	[--]	[---]
@BioBoyScout	[--]	[-----]	[--]	[---]
@BikeRieder	[--]	[-----]	[--]	[---]
@RNAiAnalyst	[--]	[------]	[--]	[---]
@jfais20	[--]	[------]	[--]	[---]
@sonichedgefund	[--]	[-----]	[--]	[---]
@Tickeron	[--]	[------]	[--]	[---]
@peter_mantas	[--]	[-----]	[--]	[---]
@ArtsStocks	[--]	[---]	[--]	[---]

Sentiment: 69%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 69%
Daily Average: 76%
[--] Week: 100% +33%
[--] Month: 77% no change
[--] Months: 77% -5%
[--] Year: 77% +20%
1-Year High: 100% on 2025-06-12
1-Year Low: 24% on 2025-03-20

Most Supportive Themes:

RNAi Technology Focus: (20%) Community discussions on the strengths and potential of RNAi therapies, comparing them to other gene-editing technologies.
Pipeline Progress & Data: (15%) Discussions highlighting promising pipeline progress and potential data releases for programs like ARO-C3 and ARO-MMP7.
Novartis Deal: (10%) Arrowhead Pharmaceuticals' global license and collaboration agreement with Novartis for the ARO-SNCA program.

Most Critical Themes:

Competitive Landscape: (10%) Frequent mentions of the competitive RNAi and broader biotech space, with comparisons to other companies.
Valuation Concerns: (5%) Some community members question Arrowhead's current valuation compared to companies with commercialized drugs.

Social Dominance: 0.021%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.021%
Daily Average: 0.021%
[--] Week: 0.0078% -0.00010000000000000113%
[--] Month: 0.021% -0.022%
[--] Months: 0.021% -0.0043%
[--] Year: 0.021% -0.0095%
1-Year High: 0.087% on 2025-11-28
1-Year Low: 0.0055% on 2025-06-14

Market Dominance: 0.01%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.01%
Daily Average: 0%
1-Year High: 0.012% on 2026-02-02
1-Year Low: 0.00206% on 2025-04-08

Market Cap: $8,936,854,366

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $8,936,854,366
Daily Average: $4,369,214,524
[--] Week: $8,893,444,387 -1.60%
[--] Month: $8,936,854,366 +0.42%
[--] Months: $8,936,854,366 +225%
[--] Year: $8,936,854,366 +261%
1-Year High: $10,222,349,870 on 2026-02-02
1-Year Low: $1,240,760,298 on 2025-04-08

Top Arrowhead Research Corporation Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"Enter: $ARWR Calls Strike Price: $65 Expiry Date: MAR [--] [----] Buy in Price: $5.50 - $6.20 Sell Price: $8.36 Profit : +52% (Turn every $1 into $1.52) Want Profitable Real-Time Options Alerts 👉 https://moneygroup.us/ https://moneygroup.us/"
X Link @OptionsAlertsAi 2026-02-15T18:09Z [---] followers, [---] engagements

"Jour [--] : Pas de nouveau trade aujourd'hui. Trades en cours (+54R latent) : $ARWR $ENPH $HYMC $LITE $SNDK $WULF 📈 Perf [----] : +527%"
X Link @CharlieQuiTrade 2026-02-11T15:56Z [--] followers, [---] engagements

"$ARWR LOL "meaningful sales." the CEO of $IONS is selling about as much in stock as Tryngolza sold this past q. Morgan Stanley looks desperate to keep the story alive for their convert holders. Parade of insider sales at @ionispharma is hard to miss. https://www.sec.gov/edgar/browse/CIK=874015&owner=exclude @semodough @ADA Morgan Stanley analyst: While early familial chylomicronemia syndrome launch trends are promising meaningful sales are not expected in 2026." $arwr $ions https://www.sec.gov/edgar/browse/CIK=874015&owner=exclude @semodough @ADA Morgan Stanley analyst: While early familial"
X Link @sonichedgefund 2026-02-09T17:24Z [----] followers, [----] engagements

"WEEKLY SHORT WATCHLIST for 2.8.26: $PBR.A $PLTD $SNDK $AJG $SKYT $EWZ $ARWR $BCE $BCRX $BHP $CRNC $FLYW $GH $LRCX $RIO $PLTR $TECK $TEVA $XLV $WT $BHP $VALE"
X Link @marcustim0thy 2026-02-08T21:47Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing